Knowledge Library
Cancer Immunotherapy and the Application of In Vitro Immunoassays in Drug Development
Optimizing Drug Discovery Pipelines with Biophysical Methods
Validation of GVHD in mouse model for preclinical efficacy screen
AACR Annual meeting 2021 Na Xu, Ya Zhang, Rou Xie, Lijun Jia, Yingying Cai, Qing Lin Oncology and Immunology Unit, WuXi AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China Background Bone marrow transplantation has been successfully and widely used to treat diseases such as leukemia and lymphomas. However, the complication Graft …Read More >
Faster with high-speed fragment screening — Accelerate your drug discovery campaign
In the past, thousands of proteins were considered undruggable. The restricted number of chemical entities available and classical methods limited the exploration of this undevelopable area. Today, the combination of novel chemical modalities and advanced technical approaches has resulted in new clinical candidates from previously undruggable targets. To accelerate your drug discovery campaign, WuXi AppTec´s …Read More >
Enabling Technology for Targeted Protein Degradation
Summary Traditional small molecule therapeutic mechanisms have recently been augmented by a new strategy to specifically manipulate the levels of disease-related proteins. By employing bifunctional molecules, we can hijack endogenous cellular degradation mechanism for targeted degradation of a disease-related protein. Bifunctional molecules consisting of a ligand that binds to an E3 ligase, connected by a …Read More >
Establishment of KRAS-G12C inhibitor induced resistant tumor models enable the development of new generation KRAS-G12C inhibitors and combinatorial strategies
Activating KRAS mutations, including G12C and G12D, are detected in approximately 25% of human cancers. The most common KRAS mutation is G12C, which comprises nearly 15% of lung adenocarcinomas, 8% of colorectal carcinomas and 4% of pancreatic adenocarcinomas. AMG-510 from Amgen and MRTX849 from Mirati Therapeutics, both targeting the KRASG12C mutant, have shown encouraging results …Read More >
Targeted Protein Degradation Platform
Integrated Services BIOLOGY & PHARMACOLOGY BINARY/TERNARY COMPLEX FORMATION Biochemical & Biophysical Assays Biochemical binding assay Cellular Assays TARGET UBIQUITINATION & DEGRADATION In vitro Assays-Target ubiquitination Target degradation assay PK/PD Animal Disease Model Evaluation CHEMISTRY Specific virtual library design Compound synthesis Conjugation and all type of custom syntheses from milligram to kilogram scale Purification and analytical …Read More >
WuXi Oncology and Immuno-Oncology Services
Integrated Oncology and Immuno-oncology Platform to Enable Translational Science from Drug Discovery to Clinical Biomarker Oncology Services CRISPR/Cas9 Gene Editing In Vitro Assay and HTS Tumor models Tumor Cell Panel and Screening Immunology and Immuno-oncology Platform Clinical Biomarker Immunology Services Ligand-receptor binding assays Cellular functional assays Assays for innate immunity pathways: macrophage, MDSC, NK, DC, …Read More >
Virology and Viral Vector Platforms
WuXi virology platforms: Immunology, Anti viral, Viral Vector, Oligo-nucleotide, Clinical and Immunology in vitro screening and profiling in vivo efficacy clinical virology Liver-specific viruses | Respiratory viruses | Herpes viruses | Other viruses
